Sirona Biochem Engages Stonegate Healthcare Partners
07 May 2024 - 10:00PM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has
announced a partnership with Stonegate Healthcare Partners.
Stonegate is a leading corporate advisory firm based in Dallas,
Texas that offers research driven business development and investor
outreach services. Leveraging Stonegate’s extensive global network
of corporate and institutional investor relationships, Stonegate
has begun an evaluation of Sirona’s anti-aging ingredient,
GlycoProteMimTM, to effectively assess and demonstrate its market
potential within the global anti-aging skincare industry.
About Sirona Biochem Corp.
Sirona is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
About Stonegate Healthare
Partners
Our mission at Stonegate Healthcare Partners is
to accelerate meaningful innovations in healthcare through
Strategy, Market Intelligence, Investor Outreach, and Business
Development. The firm's research approach is centered on
comprehensive and comparative analyses in specific healthcare
fields. We strive to pinpoint programs that align closely with our
strategic vision for the space and focus on technologies with the
greatest potential for disruption. Stonegate Healthcare builds on
its foundational thematic research by continuously gathering market
intelligence, further enabling a current understanding of unmet
needs and emerging disruptive technologies.
Our affiliates Stonegate Capital Partners and
Stonegate Capital Markets (Member FINRA/SIPC) provide institutional
investor and business development outreach, and also equity
research and investment banking advisory services. More information
can be found at www.stonegateinc.com
With five decades of experience and over 2500
institutional relationships, Stonegate currently works with ~80
public companies across a variety of sectors, and market caps for
US and non-US listed companies. Our team is composed of investment
bankers, former IROs, institutional salesmen, and research analysts
who have extensive institutional relationships. We have built
an unparalleled platform for public companies seeking to better
build and manage their institutional and corporate
relationships.
About
GlycoProteMimTM
GlycoProteMim, a novel anti-aging compound, was
developed under the direction of Dr. Géraldine
Deliencourt-Godefroy, using chemistry inspired by nature. This
compound has been clinically validated as a significant
breakthrough in non-invasive anti-aging skincare, offering powerful
rejuvenation for aged skin. Safe, effective, and easy to use,
GlycoProteMim could either complement or serve as an alternative to
Botox® and dermal fillers, depending on consumer preferences. Plans
are in place to launch the first consumer product containing
GlycoProteMim in Europe and North America through a subsidiary,
Sirona Laboratories, in early 2025, with further expansions into
other markets anticipated. More information can be found at
https://www.glycoprotemim.com.
For more information regarding this press
release, please contact:
Investor Enquiries:
Christopher HoptonChief Financial Officer
Phone: (604) 641-4466Email: info@sironabiochem.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release includes certain statements
that may be deemed “forward-looking statements”. All statements in
this new release, other than statements of historical facts, that
address events or developments that the Company expects to occur,
are forward-looking statements. Forward-looking statements are
statements that are not historical facts and are generally, but not
always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and
similar expressions, or that events or conditions “will”, “would”,
“may”, “could” or “should” occur. Although the Company believes the
expectations expressed in such forward-looking statements are based
on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from
those in the forward-looking statements. Factors that could cause
the actual results to differ materially from those in
forward-looking statements include market prices, continued
availability of capital and financing, and general economic, market
or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Forward-looking statements are
based on the beliefs, estimates and opinions of the Company’s
management on the date the statements are made. Except as required
by applicable securities laws, the Company undertakes no obligation
to update these forward-looking statements in the event that
management's beliefs, estimates or opinions, or other factors,
should change.
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Oct 2023 to Oct 2024